Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 19/20 | 0.59 |
| ▸ | CLK2 | P49760 | 4/20 | 0.59 |
| ▸ | CLK3 | P49761 | 4/20 | 0.59 |
| ▸ | WNT1 | P04628 | 8/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82928 | 0.90 | DYRK1A (0.71) | DYRK1ACLK2CLK3WNT1CSNK2A1 | |
| SCHEMBL81513 | 0.84 | DYRK1A (0.56) | DYRK1ACLK2CLK3WNT1CSNK2A1 | |
| SCHEMBL5716427 | 0.84 | DYRK1A (0.82) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL6223391 | 0.83 | DYRK1A (0.68) | DYRK1ACLK2CLK3WNT1 | |
| Hydrochloric Acid SCHEMBL952393 | 0.83 | DYRK1A (0.80) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL6222250 | 0.81 | DYRK1A (0.71) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL14792517 | 0.81 | DYRK1A (0.70) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL14803942 | 0.78 | DYRK1A (0.78) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL14804410 | 0.78 | DYRK1A (0.76) | DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL6223964 | 0.78 | DYRK1A (0.78) | DYRK1ACLK2CLK3WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | claimed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | DYRK1A 425/4885CLK2 162/4885CLK3 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.